(TOVX) Theriva Biologics, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TOVX) Theriva Biologics, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This Theriva Biologics, Inc. 4P's Marketing Mix Analysis outlines the company’s Product, Price, Place, and Promotion strategy and explains what the offering is and how it’s used. The page includes a real preview/sample of the analysis so you can evaluate style and content; purchase the full version to get the complete ready-to-use report.
Product
0 approved products
As of July 2026, Theriva Biologics had 0 approved products and remained a clinical-stage biotech, so its product mix still centered on investigational therapies, not marketed medicines. Product performance depended on trial readouts and FDA or EMA progress, with value tied to pipeline milestones rather than sales. Its strategy stayed narrow and data-driven, with no commercial product revenue to support the franchise.
SYN-004 beta-lactam degrader
SYN-004 is Theriva Biologics, Inc.'s lead anti-infective and transplant-support candidate: an enzyme designed to break down intravenously given beta-lactam antibiotics in the gut, so less drug reaches the microbiome. The goal is to cut microbiome damage, C. difficile risk, antimicrobial resistance, and acute graft-versus-host disease; the CDC estimates C. difficile causes about 223,900 U.S. infections and 12,800 deaths each year.
SYN-020 oral iAP
SYN-020 is Theriva Biologics’ oral recombinant intestinal alkaline phosphatase (iAP) candidate for localized gastrointestinal and systemic disease. It broadens the pipeline beyond antibiotic-linked programs, giving Theriva a non-oncology, non-antibiotic asset with a wider potential use case. As of the latest public filings, Theriva remained a micro-cap company, so SYN-020’s value hinges on clinical proof and partnering.
VCN-01 oncology asset
VCN-01 is Theriva Biologics, Inc.'s lead oncology asset and a key product pillar, with a pipeline that spans 4 named cancers: pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In pancreatic cancer, the hardest case, the asset is positioned in a market where the 5-year survival rate is still about 13%, which shows why the unmet need is so large.
- 4 target indications
- Lead cancer asset for Theriva Biologics, Inc.
- Focus on high-unmet-need tumors
- Pancreatic cancer remains a core value driver
Its role in the 4P's mix is clear: product differentiation comes from a multi-indication oncology platform, not a single use case. That gives Theriva Biologics, Inc. a broader clinical and commercial story, especially if later data support expansion across solid tumors.
7 investigational programs
Theriva Biologics’ product mix is built around 7 investigational programs, with SYN-006, SYN-007, SYN-005, and VCN-11 extending the pipeline beyond the lead assets. The portfolio spans aGVHD, infections, antibiotic-associated diarrhea, pertussis, and cancer, so the company is not tied to one market. This multi-indication model can spread clinical risk, but it also means capital must fund several trials at once.
- 7 investigational programs
- 5 indication areas
- Multi-indication pipeline strategy
Theriva’s Value Hinges on 2026 Pipeline Readouts
Theriva Biologics’ product mix is still pipeline-only: 0 approved products, 7 investigational programs, and value tied to 2026 clinical readouts, not sales. VCN-01 spans 4 cancers, while SYN-004 and SYN-020 anchor the non-oncology side.
| Metric | Value |
|---|---|
| Approved products | 0 |
| Investigational programs | 7 |
| Lead VCN-01 indications | 4 |
What is included in the product
Detailed Word Document
A concise, company-specific analysis of Theriva Biologics, Inc.’s Product, Price, Place, and Promotion strategy for clear strategic insight.
Editable Excel File
Condenses Theriva Biologics’ 4Ps into a quick, structured view that eases market analysis and team alignment.
Reference Sources
Provides a concise, traceable bibliography linking Theriva Biologics’ market, pricing, and competitive claims to primary industry reports, patents, and government datasets.
Place
Rockville, Maryland headquarters
Theriva Biologics' Rockville, Maryland headquarters anchors corporate, scientific, and investor work in the Washington, D.C. biotech corridor. Rockville had about 68,000 residents in the 2020 Census, and Montgomery County is a core U.S. life-science hub, so the address keeps Company Name close to talent, regulators, and capital. It also signals a firmly U.S.-based biotech footprint.
Washington University trial site
Theriva Biologics, Inc. uses Washington University School of Medicine in St. Louis as a hospital-based trial site, giving SYN-004 direct access to academic clinicians and inpatients. The clinical trial agreement supports a Phase 1b/2a study, which is the right setup for early safety and dosing work. This place strategy keeps development close to real hospital care.
Intrexon, UT Austin, Cedars-Sinai
Theriva Biologics has used institutional partners such as Intrexon, The University of Texas at Austin, and Cedars-Sinai Medical Center to support R&D, not sales distribution. Cedars-Sinai ranks among the top U.S. hospitals, and UT Austin enrolled over 52,000 students in 2025, showing the scale of the research base behind these ties. These links help fund science, trial design, and validation rather than retail reach.
U.S.-based clinical operations
Theriva Biologics, Inc. keeps its clinical operations in the U.S., using university hospitals and trial centers as investigator sites. That means patients get access through study enrollment, not pharmacies or retail channels. For a company like this, reach depends on how fast sites open, enroll, and keep trials running.
- U.S. investigator sites drive access.
- Enrollment controls therapy availability.
- Hospitals and universities anchor execution.
No commercial distribution network
Theriva Biologics, Inc. had no commercial distribution network because it remained a clinical-stage company with no approved products. Its pipeline assets were available only through research and clinical trial sites, with no retail, wholesale, or e-commerce channels.
That means there was no product shipping system, no market-facing inventory, and no customer fulfillment network. In 2025, Theriva Biologics, Inc. still depended on trial-based access rather than commercial sales.
For 4P analysis, this place strategy was effectively zero-reach outside the clinic: 0 approved products, 0 retail channels, and 0 wholesale partners.
- Clinical-stage only
- No approved-product distribution
- Trial-site access only
Theriva Biologics’ U.S.-Only Trial Footprint, No Commercial Sales
Theriva Biologics, Inc. kept Place centered on U.S. research sites in 2025, with Rockville, Maryland as its base and Washington University School of Medicine and Cedars-Sinai as trial partners. It had no approved products, so access ran only through investigator sites, not retail or wholesale channels.
| Place factor | 2025/2026 data |
|---|---|
| Headquarters | Rockville, Maryland |
| Trial access | U.S. hospital-based sites |
| Commercial channels | 0 |
Preview Before You Purchase
Theriva Biologics, Inc. Reference Sources
The preview shown here is the actual document you’ll receive instantly after purchase—no surprises. This Theriva Biologics, Inc. 4P’s Marketing Mix analysis covers Product, Price, Place, and Promotion with strategic insights, competitive context, and actionable recommendations tailored to the company’s biologics pipeline.
Promotion
Clinical trial announcements
Theriva Biologics uses clinical trial announcements as its main promotion tool, with updates on study starts and phase 1/2 or phase 2 milestones aimed at investors, investigators, and doctors. For a clinical-stage biotech with no commercial launch, each protocol start and enrollment update can be more important than ad spend. These releases help signal pipeline progress and keep the story visible.
Press releases
Theriva Biologics used press releases as a core owned-media channel in FY2025 to share partnership news and development updates, keeping SYN-004, SYN-020, and VCN-01 visible. That mattered for a company focused on just 3 named programs, where each update can shape investor attention and trial awareness.
Scientific partnerships
Scientific partnerships with universities and medical centers act as promotion for Theriva Biologics, Inc. by adding third-party validation to its pipeline. In biotech, that trust signal matters most in Phase 2 and Phase 3 programs, where outside institutions help lift clinical credibility and attract investigator interest.
Investor relations and SEC filings
Theriva Biologics, Inc. uses SEC filings and investor decks as promotion to reach capital markets and the scientific audience. Its Form 10-K, Form 10-Q, and Form 8-K updates package clinical data, risk factors, and cash needs in one place.
That matters because a micro-cap biotech must keep investors informed on trial progress and financing. Public disclosures also shape how analysts judge dilution risk, runway, and pipeline value.
- Targets investors and researchers
- Shares clinical and safety data
- Flags financing and dilution risk
October 2022 rebrand
In October 2022, Synthetic Biologics, Inc. changed its name to Theriva Biologics, Inc., refreshing its market identity and better matching its newer therapeutic focus. The rebrand supports corporate positioning by making the Company name clearer for investors, partners, and clinicians. It also helps the brand align with a narrower biotech story after the change.
- Name change completed in October 2022
- Updated identity supports market positioning
- Theriva Biologics name matches therapy focus
Theriva Biologics: Clinical Updates, Credibility, and Investor Focus
Theriva Biologics, Inc. promotes itself in FY2025 through clinical trial press releases, SEC filings, and investor decks, with SYN-004, SYN-020, and VCN-01 updates aimed at investors and researchers. Scientific partnerships add third-party trust, while the October 2022 name change to Theriva Biologics, Inc. sharpened market positioning.
| Channel | Role |
|---|---|
| Press releases | Trial updates |
| SEC filings | Risk and runway |
| Partnerships | Credibility |
Price
No approved-product pricing
Theriva Biologics, Inc. had no marketed products as of July 2026, so there was no approved-product price to quote. Without an approved therapy, there was no list price, wholesale acquisition cost, or payer contract to disclose, and pricing was not yet a customer-facing lever. In 2025, the company remained a development-stage biotech with no product revenue, so price strategy was still tied to future trial and approval milestones.
Pre-revenue model
Theriva Biologics, Inc. is still pre-revenue, so Price is not set by unit sales; in FY2025, product revenue was $0 and spending was led by R&D and clinical trial costs. That makes cash burn and financing discipline the real pricing issue, not margin per product. With no commercial anchor, value depends on pipeline progress and the ability to fund development without diluting shareholders.
Equity financing
Theriva Biologics, Inc. uses equity financing as a funding tool, not product pricing. Clinical-stage biotech firms often raise capital through stock sales and warrants because research and trials can cost tens of millions of dollars before any product revenue starts. For Theriva Biologics, this capital access helps fund R&D and clinical development, but it can also dilute existing shareholders.
Trial access at no retail price
Theriva Biologics, Inc. investigational therapies are accessed through clinical trials, so there is no retail pharmacy price. Patients do not buy a commercial therapy package; the effective cost is set by trial terms, sponsor support, and protocol-covered visits. In 2025, this means pricing is still zero at point of sale and tied to research access, not market pricing.
- No retail sale price
- Access only through trials
- Trial terms set effective cost
Future pricing undisclosed
As of July 2026, Theriva Biologics, Inc. had not disclosed commercial pricing for SYN-004, SYN-020, VCN-01, or any other pipeline asset. Any launch price would still depend on FDA approval, indication, dose schedule, and payer reimbursement, so the pricing framework remained undefined.
- Commercial price: not published
- Depends on approval and indication
- Reimbursement still unknown
- Pricing framework undefined in July 2026
Theriva Biologics Had No Commercial Price in FY2025
Theriva Biologics, Inc. had no approved products in FY2025 or as of July 2026, so Price was still $0 at the point of sale. With no product revenue in 2025, there was no list price, WAC, or payer contract to disclose. Any future price would depend on FDA approval, label, and reimbursement.
| Price item | FY2025 / Jul 2026 |
|---|---|
| Product revenue | $0 |
| Commercial price | Not disclosed |
| Market access | Clinical trials only |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.